XML 107 R92.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Per Common Share (Computation Of Basic And Diluted Income Per Common Share) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2017
 [1]
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
 [2]
Sep. 30, 2016
 [2]
Jun. 30, 2016
 [2]
Mar. 31, 2016
 [2]
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                              
Net income $ (3,007) $ 1,325 $ 3,163 $ 2,223 $ 2,897 $ 2,993 $ 2,347 $ 2,541 $ 2,636 $ 2,145 $ (502) $ (274) $ 3,704 $ 10,778 $ 4,005
Net income allocated to participating securities                         (63) (208) (87)
Net income allocated to common shareholders                         $ 3,641 $ 10,570 $ 3,918
Basic weighted-average common shares outstanding                         33,008,000 31,855,000 27,744,000
Basic income per common share                         $ 0.11 $ 0.33 $ 0.14
Net income allocated to participating securities, diluted                         $ (61) $ (202) $ (87)
Net income allocated to common shareholders, diluted                         $ 3,643 $ 10,576 $ 3,918
Effect of dilutive stock options and awards                         1,155,000 967,000 798,000
Diluted weighted-average common shares outstanding                         34,163,000 32,822,000 28,542,000
Diluted income per common share $ (0.09) $ 0.04 $ 0.09 $ 0.06 $ 0.09 $ 0.09 $ 0.07 $ 0.08 $ 0.09 $ 0.07 $ (0.02) $ (0.01) $ 0.11 [3] $ 0.32 [3] $ 0.14 [3]
Stock Options [Member]                              
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                              
Antidilutive securities excluded from computation of earnings per share                         227,000 1,000 710,000
[1] In December 2017 we completed our acquisition of JOTEC, which is also being operated as a wholly owned subsidiary of CryoLife.
[2] In January 2016 we completed our acquisition of On-X Life Technologies Holdings, Inc., which is being operated as a wholly owned subsidiary of CryoLife. In 2016 we also sold our HeRO Graft product line and our ProCol product line, and ceased sales of these products during 2016.
[3] We excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares, because the inclusion of these stock options would be antidilutive to income per common share. Accordingly, stock options to purchase 227,000, 1,000, and 710,000 shares for the years ended December 31, 2017, 2016, and 2015, respectively, were excluded from the calculation of diluted weighted-average common shares outstanding.